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Summary 
Relapsing experimental autoimmune encephalomyeli- 
tis (R-EAE) induced with the immunodominant epitope 
from proteolipid protein, PLPIJo-151, ischaracterized by 
the development of recurrent relapses with recruit- 
ment of T cells reactive to additional myelin peptides, 
including PLP178-101 (epitope spreading). In this study, 
we have determined that the CD2g/B7 costimulatory 
pathway is involved in this process. We found prefer- 
ential up-regulation of 87-l during the course of R-EAE 
and a selective increase in its functional costimulatory 
activity, relative to 87-2. Anti B7-1 F(ab) fragment ther- 
apy, but not anti 87-2 MAb therapy, blocked clinical 
relapses, ameliorated CNS pathology, and blocked 
epitope spreading. These results suggest that the 
maintenance of autoimmune reactivity in EAE depends 
on CD28/B7-l-dependent costimulation of newly re- 
cruited T cells responsible for epitope spreading. 
These studies have important implications for the role 
of epitope spreading in disease progression and the 
clinical application of costimulatory antagonists in au- 
toimmune diseases. 
Introduction 
Relapsing experimental autoimmune encephalomyelitis 
(R-EAE) is an inflammatory demyelinating disease of the 
central nervous system (CNS), which is mediated by neu- 
roantigen-specific CD4+ T cells and serves as a model for 
the human demyelinating disease, multiple sclerosis (MS) 
(Gonatas et al., 1966; Wekerle, 1991). R-EAE can be in- 
duced in the SJL mouse by active immunization with the 
dominant encephalitogenic epitope of myelin proteolipid 
protein (PLP139..151) (Tuohy et al., 1969; McRae et al., 1992) 
or by adoptive transfer of PLP139-15,-specific T cells to naive 
recipients (McRae et al., 1992). Both induction methods 
lead to CNS inflammatory infiltrates dominated by mono- 
nuclear cells and to primary demyelination of axonal 
tracks. The relapsing-remitting course of paralysis is char- 
acterized by a moderate to severe initial acute phase of 
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disease followed by recovery and subsequent clinical re- 
lapses. As recently demonstrated by us and others, the 
emergence of autoaggressive T cells reactive to myelin 
epitopes presented to the immune system as a result of 
CNS damage during the initial clinical disease (termed 
epitope spreading) appears to be capable of mediating 
clinical relapses in progressive EAE (Perry and Barzaga, 
1987; Lehmann et al., 1993; Tan et al., 1991). For instance, 
in PLPlsglsI-induced R-EAE, we have demonstrated the 
appearance of T cells specific for the noncross-reactive 
PLP178-191 epitope following recovery from acute disease. 
These autoreactive T cells have potent encephalitogenic 
potential upon transfer to naive recipient mice (Miller et 
al., 1995; McRae et al., 1995). 
Recent studies have shown that T cell activation re- 
quires both T cell receptor (TCR) engagement and delivery 
of costimulatory signals. Among these signals, those me- 
diated via the CD28/B7 pathway appear to be most critical, 
since the blockade of this pathway results in the induction 
of antigen-specific unresponsiveness, or anergy, both in 
vitro and in vivo (Jenkins and Schwartz, 1987; Mueller et 
al., 1989; Lenschowet al., 1992; Linsleyet al., 1992; Finck 
et al., 1994; Miller and Karpus, 1994). Treatment with 
CTLA-419, a soluble CD28 antagonist that binds to both 
CD28 ligands, 87-l (Linsley et al., 1990, 1991) and 87-2 
(Lenschow et al., 1993; Hathcocket al., 1993), suppresses 
both allogeneic and xenogeneic transplant rejection 
(Lenschow et al., 1992, 1995b; Lin et al., 1993) inhibits 
antibody responses to T-dependent antigens (Linsley et 
al., 1992) and prevents the initiation of autoimmune dis- 
ease in murine models of EAE, diabetes, and lupus (Perrin 
et al., 1995; Lenschow et al., 1995a; Finck et al., 1994). 
However, little is known about the role of CD28/B7 interac- 
tions in ongoing autoimmune processes. Recent studies 
have suggested that the 87-l and 87-2 molecules may 
regulate immune responses differentially. 87-2 plays a 
dominant costimulatory role in initiating immune reactions 
(Lenschow et al., 1995a, 1995b; Walunas et al., 1994), 
while B7-1 has been proposed to be the major costimula- 
tory molecule during persistent infections or chronic in- 
flammatory conditions (Bluestone, 1995; June et al., 
1994). In the present study, we assessed the roleof costim- 
ulation in the pathogenesis of ongoing R-EAE. The results 
suggest that epitope spreading is an essential component 
in the establishment of recurrent disease; that 87-l be- 
comes the dominant costimulatory ligand following the ini- 
tial acute clinical episode; and that 87-l blockade effec- 
tively inhibits epitope spreading and disease relapses in 
PLP139-151-primed mice. 
Results and Discussion 
Enhanced Phenotypic and Functional Expression of 
B7-1 on CNS-Infiltrating Mononuclear Cells and 
Splenic APCs in Mice with R-EAE 
Studies over the past few years have shown that both 67-l 
and 87-2 are tightly regulated on different antigen- 
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presenting cells (APCs). In vitro, we have shown that 67-2 
is rapidly induced (within 6 hr) on activated B cells, while 
67-l expression cannot be detected until 2 to 3 days after 
6 cell activation (Lenschow et al., 1994). Cytokines such 
as interleukin-4 (IL+, interferon-y, and IL-5 profoundly al- 
ter the expression of 87-l and 87-2. Thus, the temporal 
expression of 87 molecules during a chronic inflammatory 
response may be quite distinct from that observed in 
healthy animals. Moreover, treatment of animals with 
CD26/B7 antagonists may have differential effects during 
different stages of disease progression. Therefore, we ex- 
amined the cell surface expression of 87-l and 87-2 on 
macrophages (F4/80+), B cells (B220+), and T cells (CD3+) 
from spleens of naive SJUJ mice and from the CNS and 
spleens of mice, immediately prior to the onset of acute 
EAE (preclinical) and in remission following acute disease. 
Typically, in naive mice, the expression of 87-2 on splenic 
B cells, dendritic cells, and macrophages is significantly 
greater than 87-i (Lenschow et al., 1994). Similar results 
were observed in the SJUJ strain, wherein 87-2 expression 
was generally P-fold greater than 87-l on splenic APCs 
(Figure 1A). In contrast, the induction of EAE in these ani- 
mals had a profound effect on the relative expression of 
the two molecules. The relative expression of 87-l signifi- 
cantly increased on splenocytes (B cells as well as macro- 
phages) from mice at the time of peak clinical disease as 
well as during the remission phase following acute disease 
(data not shown). Interestingly, the increased 87-l expres- 
sion was even more pronounced in the CNS, where the 
inflammatory response is localized (Figures 1A and 1 B). 
It was not possible to determine the levels of B7expression 
on CNS cells from naive mice since only a few cells can 
be recovered. However, as seen in Figure 1 B, the percent- 
age of CNS-infiltrating mononuclear cells expressing 87-l 
was significantly greater than those expressing 87-2 in 
mice with EAE at both the preclinical (top, 81% versus 
24%) and remission (bottom, 57% versus 42%) stages. 
In addition, the ratio of 67-1 to 87-2 expression was also 
greatly enhanced on CNS-infiltrating cells, particularly 
those isolated at the preclinical stage, in comparison to 
that observed on naive SJUJ splenocytes. Further, exami- 
nation of 87 expression on cell subsets infiltrating the CNS 
(Figure 1A) revealed that 87-l expression was enhanced 
on F4/80+ macrophages (top) and CD3+ T cells (bottom), 
which together make up >95% of the infiltrates with peak 
expression occurring just prior to the acute disease. 87-l 
expression was also enhanced on the few (t 5%) CNS- 
infiltrating B220+ B cells (Figure lA, middle), with peak 
expression occurring at the time of remission. These re- 
sults provide evidence that expression of 87-1, in compari- 
son to 87-2, is significantly augmented during a chronic 
T helper 1 (Thl)-mediated inflammatory autoimmune dis- 
ease, predominantly on cells infiltrating the target organ. 
B7-2, not 87-1, is thought to be the primary costimula- 
tory molecule responsible for initiating an immune re- 
sponse (Lenschow et al., 1995a, 1995b). Yet, in the pres- 
ent study, 87-l was profoundly up-regulated during R-EAE 
disease progression. Therefore, the functional costimula- 
toryactivityof thedifferent APCswasdetermined byexam- 
ining the ability of antiB7-1 and anti-B7-2 to block an allo- 
geneic mixed lymphocyte reaction (MLR) stimulated by 
irradiated splenocytes from naive mice in comparison to 
mice with acute or remitted EAE (Figure 2). In agreement 
with our previous report (Lenschow et al., 1994), anti-B7-2 
monoclonal antibody (MAb) blocked the primary MLR of 
B6 T cells stimulated by splenocytes from naive mice. 
However, in this study using SJUJ mice, anti-B7-1 also 
partially blocked the primary MLR, which may reflect the 
differences in the strains of mice used as stimulators in 
the two studies, SJLIJ mice having higher endogenous 
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Figure 1. Enhanced Expression of 87-l on 
CNS-Infiltrating Macrophages and B Cells of 
Mice with Preclinical EAE and in Remission 
following Acute Disease 
Splenocytes from naive SJW mice and CNS- 
infiltrating mononuclear cells from mice just 
prior to acute EAE onset (preclinical) and in 
remission from acute disease (remission) were 
analyzed for levels of expression of 87-l and 
87-2 on F4/80+ macrophages. B cells, and T 
cells by two-color flow cytometry. 
(A) Relative levels of 87-l and 87-2 expression 
on macrophages (top), B cells (middle), and T 
cells (bottom) isolated from naive SJUJ spleen 
and from CNS-infiltrating mononuclear cells 
during the preclinical and remission stages of 
R-EAE is shown. Data is plotted as the mean 
fluorescence shift above background. The ratio 
of the expression levels of B7-l:B7-2 is indi- 
cated in parentheses above each pair of bars. 
(B) Levels of expression of 87-l (antiCD80) 
and 87-2 (anti-CD 86) on total CNS mononu- 
clear cells collected from mice immediately 
prior to disease onset (top) and from mice in 
remission (bottom) are shown. The percent- 
ages of positive cells are shown in paren- 
theses. 
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Figure 2. 87-l Becomes the Dominant Costimulatory Molecule on 
Splenic APCs from SJUJ Mice with Acute EAE and in Remission fol- 
lowing Acute Disease 
Splenocytes were harvested from naive SJUJ mice and from mice at 
the peak of acute EAE and in remission following recovery from acute 
disease. Irradiated splenocytes (4 x 106) from naive SJUJ mice and 
from mice at various stages of EAE were used to stimulate 2 x 105 
purified C57BU6 T cells in the presence of 106 ug/ml of purified anti- 
87-l (1610Al). anti-B7-2 (GL-I), or a combination of these MAbs. 
Control cultures contained 100 uglml each of rat and hamster isctype- 
matched control immunoglobulin. 
levels of 87-l expression on splenic APCs. The combina- 
tion of the two antibodies totally abrogated the response. 
Interestingly, the proliferation of 66 T cells stimulated with 
splenocytes from mice with acute EAE or in disease remis- 
sion was blocked more efficiently by anti-B7-1 than by 
anti-67-2 MAbs. In fact, anti-B7-2 MAb had little or no effect 
on the proliferative response when the B6 T cells were 
cultured with splenic APCs from mice in disease remission 
(Figure 2). Thus, the enhanced functional costimulatory 
role of 87-l in mice undergoing chronic inflammation 
roughly correlates with the enhanced expression of 87-l 
observed on splenic B cells and macrophages and on in- 
flammatory cells infiltrating the CNS of mice at different 
stages of clinical EAE. 
Treatment with Anti-87-l F(ab) Fragments Blocks 
Disease Relapses 
Based on the phenotypic and functional studies, it ap 
peared that 87-1, rather than B7-2, might be involved in 
T cell costimulation after the acute phase of the disease. 
Therefore, we examined the effects of treatment with 
MAbs directed against 87-l following recovery from the 
initial disease episode. Previous studies in the EAE and 
the autoimmune diabetes models have utilized treatments 
with intact anti 87-l MAb with apparently conflicting re- 
sults (Lenschow et al., 1995a; Kuchroo et al., 1995). One 
of the several explanations for these findings is the possi- 
bility of direct signaling by the intact antibody. Therefore, 
to ensure blockade of the CD26/B7-1 interaction, we used 
the F(ab) fragments of anti-B7-1 MAb. Administration of 
F(ab) fragments resulted in significant protection from de- 
velopment of clinical relapses (Figure 3). Combined data 
from two separate experiments employing 50 ug per dose 
showed that a significantly lower (p = 0.016) proportion 
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Figure 3. Treatment with the F(ab) Fragment of Anti-B7-1 Blocks the 
Development of Clinical Relapses in PLP,,,,,-Induced Active R-EAE 
Following recovery from the acute paralytic episode (day +25), groups 
of 6-8 SJUJ mice each were treated with a total of 250 pg (five treat- 
ments of 50 PQ every other day) of rat control immunoglobulin, the 
F(ab) fragment of anti 87-l MAb 16-lOA or anti-87-2 MAb GL-I, and 
monitored for development of clinical relapses for an additional 25 
days. The results are expressed as the relapse rate (mean number 
of relapses/total number of mice in each treatment group) versus days 
post antibody treatment. The relapse incidence in the 16lOA F(ab)- 
treated group (1 of 6) was significantly less than that of the controls 
(6 of 8) p = 0.05 by x2. The data are representative of two separate 
experiments. 
of 161OAl F(ab)-treated mice exhibited relapses (3 of 14 
[21%] with a mean day of onset of 42.7 f 2.1 days) com- 
pared with rat immunoglobulin-treated controls (10 of 15 
[66%] with a mean day of onset of 44.4 -c 4.6 days). 
In contrast with the effects of anti-B7-1 MAb, treatment 
of mice with the anti-B7-2 MAb, GL-1, had no appreciable 
effect on the incidence or severity of clinical relapses when 
administered during the remission following acute disease 
(Figure 3). Our results differ from those recently reported 
by Kuchroo et al. (1995), in which treatment with anti-B7-2 
at the time of induction of active EAE was shown to in- 
creass disease severity, and from studies done in the NOD 
model, in which treatment with anti-B7-2 prior to disease 
onset was shown to reduce disease severity (Lenschow 
et al., 1995a). Thus, the functional roles of 87-l and 87-2 
in providing costimulation apparently differ depending on 
whether the animal is immunologically naive or is undergo- 
ing a chronic inflammatory disease such as R-EAE. 
Histological examination of the CN$ demonstrated that 
treatment of mice with F(ab) fragments of the anti-B7-1 
MAb decreased both the inflammatory response and de- 
myelination, when compared with control mice (Figure 4). 
Therefore, the ameliorating effect of the anti-B7-1 therapy 
is a direct consequence of the regulation of T cell-medi- 
ated inflammation and demyelination. 
Mechanism of Anti-B7-1 F(ab)-Mediated Abrogation 
of Disease Relapses 
The profound effect of anti-B7-1 MAb therapy on disease 
relapses suggests that costimulation is involved in the evo- 
lution of the inflammatory response in this model. Our re- 
cent studies have shown that, in addition to T cells specific 
for the primary immunogen (PLP,~Q..w), T cells activated 
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Figure 4. Histologic Analysis of Spinal Cord Sections from Anti-B7-I F(ab)-Treated Mice 
Spinal cords from 2-3 mice per group were examined for histologic signs of mononuclear cell infiltration and demyelination at approximately 50 
days postimmunization. A typical chronic lesion of demyelination with little residual activity is seen in a spinal cord section from a mouse treated 
with rat control immunoglobulin (A). In contrast, minimal lesions with only a few dark myelin figures were observed in sections from mice treated 
with 131OAl F(ab) fragments (6). (A) and (B) are 1 urn thick, Epon-embedded sections stained with toluidine blue. Original magnification. 250x. 
via epitope spreading to other noncross-reactive myelin- 
derived peptides (e.g., PLPv~-,~,) contribute to the relaps- 
ing pathology in this R-EAE model. In fact, recent studies 
have suggested that these T cells play a critical role in the 
clinical relapses (Miller et al., 1995; McRae et al., 1995). 
Therefore, we evaluated the effect of anti 67-l F(ab) 
therapy on epitope spreading by examining the delayed- 
type hypersensitivity (DTH) response to the initiating 
(PLPIS15,) myelin epitope and to the recruited (PLPInr-,sI) 
myelin epitope in control and MAb-treated inice. These 
studies were performed both immediately following the 
cessation of the anti 87-l F(ab) treatment, a timepoint prior 
to the onset of disease relapses in either the control or 
treated groups (data not shown), as well as 49 days after 
the initial peptide injection, to coincide with the first relapse 
in the controls. There was no significant difference in the 
DTH responses between the groups to the initiating epi- 
tope PLPOWSI (Figure 5). In contrast, the development of T 
cell reactivity to the relapse-associated PLP,,,#, epitope 
was virtually eliminated by the treatment with anti-87-l 
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Figure 5. Treatment with the F(ab) Fragment of Anti-BF1 Blocks the 
Development of Epitope Spreading to the Secondary PLP,,e.rsI Deter- 
minant 
DTH responses to PLP139-151 or PLP 178-1r,1 were assessed in groups of 
3-4 mice each on day +49 post disease induction. The results are 
expressed as A 24 hr ear swelling (background swelling subtracted) 
in units of 10.’ in f SEM. Background ear swelling responses in 
unimmunized mice (n = 3 for each experiment) were 7.4 f 3.4 U for 
PLPl,lsI, and 5.4 f 3.2 U for PLP,,~rlr. Asterisk, DTH response in 
anti-87-i F(ab)-treated mice to PLP 1,8-1sl was significantly reduced 
compared with the rat immunoglobulin-treated controls (p < 0.01, Stu- 
dent’s t test). These results are representative of two separate experi- 
ments. 
F(ab) fragments. These results suggest that the anti-67-l 
MAb primarily affects the recruitment of naive T cells re- 
sponsible for the epitope spreading and clinical relapses 
and not the activated PLP1~ISl-reactive Tcells. Therefore, 
these data suggest that inhibition of epitope spreading has 
a profound effect on the clinical course of a progressive 
autoimmune disease. 
Collectively, the present data are consistent with a 
model wherein the expression of 87-l is enhanced relative 
to 87-2 during the acute and chronic stages of an inflam- 
matory autoimmune disorder. Therefore, anti-B7-2 MAbs 
may be most effective at blocking or skewing Tcell-depen- 
dent immune responses during their initiation at a time 
when 87-l expression is limited, whereas B7-1 becomes 
the functionally dominant costimulatory molecule involved 
in perpetuation of disease pathogenesis. This model is 
supported by our recently published results wherein anti- 
87-2 was effective in ameliorating the onset of diabetes 
in NOD mice, but not in mice >I 0 weeks of age (Lenschow 
et al., 1995a). Furthermore, in the R-EAE model, 87-l may 
function as adominant costimulatory molecule involved in 
the local CNS presentation of antigen to encephalitogenic 
effectorT cells and in signaling the recruitment and activa- 
tion of naive T ceils specific for secondary myelin peptides 
exposed during the first clinical episode. Therefore, the 
use of antagonists of costimulation for treatment of chronic 
autoimmune diseases is promising, but requires a more 
complete understanding of the temporal and functional 
roles of the individual CD28 ligands during the course of 
disease. The relapsing nature of EAE in the SJUJ mouse 
makes it an ideal system to study the effects of modifying 
costimulatory signals in animals with a preexisting autoim- 
mune disease. 
Expsrlmental Procedures 
Mice 
Female SJUJ mice, 9-7 weeks old, were purchased from Harlan Labo- 
ratories, Indianapolis, Indiana. All mice were housed in the Northwest- 
ern University animal care facility and were maintained on standard 
laboratory food and water ad libitum. Paralyzed mice were afforded 
easier access to food and water. 
Psptldes 
PLP js16I (HSLGKWLGHPDKF) and mouse PLP,7b,9, (NTWTTCQSI- 
AFPSK) were synthesized using a RaMPS Multiple Peptide Synthesis 
System (New England Nuclear-DuPont, Wilmington, Delaware). 
Amino acid composition of these peptideswas confirmed by the North- 
western University Biotechnology Center. PLP,,,,,M was insoluble 
in phosphate-buffered saline (PBS) and wasdissolved in 0.035 M ace- 
tic acid (Greer et al., 1992). 
lnductlon of R-EAE by Active lmmunlzstlon wlth PLP,,,aI 
Mice were immunized with PLP l~,sl in adjuvant as previously da 
scribed (McRae et al., 1992). Each mouse received 100 ul of a com- 
plete Freund’sadjuvant emulsion containing 200 pg of Mycobactsrium 
tuberculosis H37Ra (Difco) and 50 nmol(97 ug) of PLPI+o-rsr distributed 
over three spots on the flank. 
Cllnlcal Evaluation 
Mice were scored according to their clinical severity as follows: grade 
0, no abnormality; grade 1, limp tail; grade 2, limp tail and hind limb 
weakness (waddling gait); grade 3, partial hind limb paralysis; grade 
4, complete hind limb paralysis; and grads 5. moribund. The data are 
plotted as the mean daily clinical score for all animals in a particular 
treatment group. In some instances, the mean maximal clinical score 
per group is given as an indication of disease severity. A relapse was 
defined as a sustained increase of at least one full grade in clinical 
score after the animal had previously improved at least a full clinical 
score and had stabilized. 
Hlstologlc Evaluatlon 
Mice were anesthetized with sodium pentobarbital and sacrificed by 
total body perfusion through the left ventricle with chilled 3% glutaral- 
dehyde in phosphate buffer (pH 7.3). Spinal cords were removed by 
dissection and cut into 1 mm thickcross-sections, which were postfixed 
in 1% OsO&, dehydrated, and embedded in Epon as previously de 
scribed (Dal Canto and Lipton, 1975). Toluidine blue stained sections 
from 10-l 1 segments per mouse were read blind and scored as fol- 
lows: plus/minus, mild inflammation without demyelination; l+, inflam- 
mation with focal demyelination; 2+, inflammation with multiple foci of 
demyelination; 3+, marked inflammation with bilateral converging ar- 
eas of dsmyelination; 4’. extensive bilateral areas of dsmyelination 
and remyelination. The scores for each segment were used to quanti- 
tate the histopathologic involvement for each animal. 
In Vlvo Antibody Treatment 
The following MAbs were employed: rat control immunoglobulin (11 I/ 
10); hamster control immunoglobulin (ParsilP), the anti-CD&l (87-l) 
MAbs, lGlO(Nabavietal., 1992) and 151OAl (Repligencorporation); 
and the anti-CD99 (87-2) MAbGL-1 (Hathcock et al., 1993). Antibodies 
were produced in an Acusyst Jr. bioreactor and F(ab) fragments of 
anti-B7-1 MAb 1910Al were produced and purified as previously de- 
scribed (Lenschow et al., 1995a; Walunas et al., 1994). Mice were 
treated following recovery from the initial paralytic episode of R-EAE 
(20-25 days post-immunization). Antibody (50 9g) was administered 
intraperitoneally every other day for five treatments (250 pg total) and 
mice were monitored for development of clinical relapses for an addi- 
tional 40-90 days. 
Isolstlon of CNS-lnflltmtlng Mononuclssr Cells and Splsnocytss 
Mice were anesthetized with methoxyflurane and perfused through 
the left ventricle with -90 ml of PBS. Spinal cords were extruded by 
flushing the vertebral canal with PBS, and rinsed in PBS. Spleens 
were removed from the same mice and placed in PBS. Tissues were 
forced through lOO-mesh stainless steel screens to give a single cell 
suspension. Red blood cells in spleen cell preparations were lysed 
by hypotonic shock in Tris-NHCI and the cells were washed and 
resuspended in MAb 2.4G2 (anti-mouse FcRylUIII) supernatant con- 
taining 5% normal mouse serum. CNS mononuclear cells were iso- 
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lated by centrif.ugation (500 x g) at 24°Cover30%/70% discontinuous 
Percoll (Pharmacfa) gradients. Cells collected from the 30%/70% inter- 
face were washed and resuspended in 2.462 supernatant. 
Flow Cytometry 
Fluorescein isothiocyanate (FITQconjugated MAbs to CD3 (T cells) 
and 8220 (B cells) were purchased from Pharmingen (La Jolla, Califor- 
nia). FITC-anti-F4/60 (macrophage/microglial cells) was purchased 
from Caltag(South San Francisco, California). Purified anti-B7-1 (clone 
16-1OAl) and anti-B7-2 (GL-1) MAbs were biotinylated using NHS- 
LC-biotin (Pierce, Rockford, Illinois). Avidin-R-phycoerythrin (A-PE) 
was purchased from Molecular Probes (Eugene, Oregon). Cells (2.5- 
II x IO’ CNS mononuclear cells or lOa splenocytes) were incubated 
with a predetermined optimal concentration of biotinylated anti-B7 
MAb in 2.402 supernatant for 30 min at 4OC. Cells were washed in 
isotonic-buffered saline (Baxter; containing 0.1% NaN3 and 1.0% nor- 
mal goat serum) followed by incubation with A-PE and the appropriate 
FITC-conjugated MAb (antiCD3, anti-8220, or anti-F4/60) for 30 min 
at 4°C in thedark. Cellswere washedand resuspended in 1 ml isotonic- 
buffered saline containing 0.1 uglml propidium iodide. Data collection 
and analysis were performed on a FACScan flow cytometer (Becton- 
Dickinson, MountainView, California). Sufficienteventswerecollected 
to assure that at least 4 x 103 large mononuclear cells were analyzed 
per sample. Nonspecific staining was determined by incubating sam- 
ples with the appropriately conjugated isotype-matched control MAbs. 
MLR Assay 
SJUJ splenocytes (4 x 105) isolated from SJUJ mice at different 
stages of disease were irradiated (2006 rads) and incubated with 106 
pg/ml of blocking or control antibodies for 15 min prior to the addition 
of 2 x lo5 purified C57BU6 T cells. Cultures were incubated at 37OC 
for 4 days and pulsed with 1 uCi/well of PH]thymidine for the final 16 
hr. Proliferation is presented as the mean cpm of triplicate wells. SEMs 
were <IO%. 
Ag-Specific DTH 
DTH responses were quantitated using a 24 hr ear swelling assay 
(f&Rae et al., 1992). Prechallenge ear thickness was determined us- 
ing a Mitutoyo model 7326 engineers micrometer (Schlesinger’s Tools, 
Brooklyn, New York). Immediately thereafter, DTH responses were 
elicited by injecting 5 pg of peptide (in 10 cl of saline) into the dorsal 
surface of the ear using a 106 cl Hamilton syringe fitted with a 30 
gauge needle. The increase in ear thickness over prechallenge mea- 
surements was determined 24 hr after ear challenge. Results are ex- 
pressed in units of 10’ inches f SEM. Ear swelling responses were 
the result of mononuclear cell infiltration and showed typical DTH kinet- 
ics (i.e., minimal swelling at 4 hr, maximal swelling at 24-46 hr). 
Statistical Analyses 
Comparison of the percentage of animals showing clinical relapses 
between any two groups of mice were analyzed by x2 using Fisher’s 
exact probability. Comparisons of the mean day of onset of relapse, 
mean peak disease severity, and DTH responses between any two 
groups of mice were analyzed by the Student’s t test. p values < 0.05 
were considered significant. 
Theileh virus infection: an ultrastructural study. Lab. Invest. 33,626 
637. 
Finck, B.K., Linsley, P.S., and Wofsy, D. (1994). Treatment of murine 
lupus with CTLA4lg. Science 265, X225-1227. 
Gonatas, N.K., Greene, MI., and Waksman, B.H. (1966). Genetic and 
molecular aspects of demyelination. Immunol. Today 7, 121-126. 
Greer, J.M., Kuchroo, V.K., Sobel, R.A., and Lees, M.J. (1992). Identifi- 
cation and characterization of a second encephalitogenic determinant 
Of myelin proteolipid protein (residues 176-l 91) for SJL mice. J. Immu- 
nol. 149, 763-766. 
Hathcock, K.S., Laszlo, G., Dickler, H.B., Bradshaw, J., Linsley, P., 
and Hodes, R.J. (1993). Identification of an alternative CTLA-4 ligand 
costimulatory for T cell activation. Science 262. 905-907. 
Jenkins, M.K., and Schwartz, R.H. (1967). Antigen presentation by 
chemically modified splenocytes induces antigen-specific T cell unre- 
sponsiveness in vitro and in vivo. J. Exp. Med. 165, 302319. 
June, C.H., Bluestone. J.A., Nadler, L.M., and Thompson, C.B. (1994). 
The 87 and CD26 receptor families. Immunol. Today 15, 321-331. 
Kuchroo, V.K., Das, M.P., Brown, J.A., Ranger, A.M., Zamvil, S.S., 
Sobel, R.A., Weiner, H.L., Nabavi, N., andGlimcher, L.H. (1995). 87-l 
and 87-2 costimulatory molecules differentially activate the ThlmhP 
developmental pathways: application toautoimmune disease therapy. 
Cell 80, 707-716. 
Lehmann, P.V., Sercarz. E.E., Forsthuber, T., Dayan, CM., and Gam- 
mon, G. (1993). Determinant spreading and the dynamics of the auto- 
immune T-cell repertoire. Immunol. Today 14.203-206. 
Lenschow, D.J., Zeng, Y., Thistlethwaite, J.R., Montag, A., Brady, W., 
Gibson, M.G., Linsley, P.S., and Bluestone, J.A. (1992). Long-term 
survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. 
Science 257, 769-792. 
Lenschow, D.J., Su, G.H., Zuckerman, L.A., Nabavi, N., Jellis, C.L., 
Gray, G.S., Miller, J., and Bluestone, J.A. (1993). Expression and func- 
tional significance of an additional ligand for CTLA-4. Proc. Natl. Acad. 
Sci. USA 90, 11054-11058. 
Lenschow. D.J., Sperling, A.I., Cooke, M.P., Freeman, G., Rhee, L., 
Decker, DC., Gray, G., Nadler, L.M., Goodnow, C.C., and Bluestone. 
J.A. (1994). Differential up-regulation of the 87-l and 872 costimula- 
tory molecules after lg receptor engagement by antigen. J. Immunol. 
153.1990-1997. 
Lenschow, D.J., Ho, SC., Sattar, H., Rhee, L., Gray, G., Nabavi, N., 
Herold, KC., and Bluestone, J.A. (1995a). Differential effects of anti- 
87-l and anti-87-2 MAb treatment on the development of diabetes in 
the NOD mouse. J. Exp. Med. 787, 1145-1155. 
Lenschow, D.J., Zeng, Y., Hathcock, K., Zuckerman, L.A., Freeman, 
G., Thistlethwaite, J.R., Barrett, T.A., Gray, G.S., Hodes, R.I., and 
Bluestone, J.A. (1995b). Inhibition of transplant rejection following 
treatment with anti-87-2 and anti-B7-1 antibody. Transplantation 60, 
in nress 
.‘. r.---. Lin, H., Bolling, S.F., Linsley. P.S., Wei, R.Q., Gordon, D., Thompson, 
C.B.. and Turka, L.A. (1993). Long-term acceptance of major histocom- 
patibility complex mismatched cardiac allografts induced by CTLA4lg 
plus donor-specific transfusion. J. Exp. Med. 778, 1601-1806. 
Acknowledgments 
The authors thank Drs. W. J. Karpus, C. Thompson, A. Sperling, and 
K. Nikcevich for their thoughtful reviews of the manuscript. This work 
was supported in part by United States Public Health Service National 
Institutes of Health research grants NS30671, NS26543, Al35294, 
CA40216, Al35225 and a grant from Repligen Corporation. J. G. P. 
is a Howard Hughes Medical Institute predoctoral fellow. 
Received February 14, 1995; revised October 26, 1995. 
antigen 87188-l. Proc. Natl. Acad. Sci. USA 87. 5031-5035. 
Linsfey, P.S., Brady, W., Grosmaire, L., Aruffo. A.. Damle, N.K., and 
Linsley, P.S., Clark, E.A., and Ledbetter, J.A. (1990). T-cell antigen 
Ledbetter, J.A. (1991). Binding of the B cell activation antigen 87 to 
CD26 mediates adhesion with B cells by interacting with activation 
CD28 costimulates T cell proliferation and interleukin 2 mRNA accu- 
mulation. J. Exp. Med. 773. 721-730. 
Linsley, P.S., Wallace, P.M., Johnson, J., Gibson, M.G., Greene, J.L., 
Ledbetter, J.A., Singh, C., and Tepper, MA. (1992). Immunosuppres- 
sion in vivo by a soluble form of the CTLA4 T cell activation molecule. 
Science 257, 792-795. 
References 
McRae, B.L., Kennedy, M.K.. Tan, L.J., Dal Canto, MC., and Miller, 
S.D. (1992). Induction of active and adoptive chronic-relapsing experi- 
Bluestone, J.A. (1995). New perspectives of CD26-B7-mediated T cell mental autoimmune encephalomyelitis (EAE) using an encephalito- 
costimulation. Immunity 2, 555-559. genie epitope of proteolipid protein. J. Neuroimmunol. 38, 229-240. 
Dal Canto, M.C., and Lipton, H.L. (1975). Primary demyelination in McRae, B.L., Vanderlugt. C.L., Dal Canto, MC., and Miller. S.D. 
;y5atment of Relapsing EAE by Blockade of CD29/B7-1 Interaction 
(1995). Functional evidence for epitope spreading in the relapsing 
pathology of EAE in the SJUJ mouse. J. Exp. Med. 782. 75-85. 
Miller, B.D., and Karpus, W.J. (1994). The immunopathogenesis and 
regulation of T-cell mediated demyelinating diseases. Immunol. Today 
l&356-351. 
Miller, SD., f&Rae, B.L., Vanderlugt. CL., Nikcevich, KM., Pope, 
J.G., Pope, L., and Karpus, W.J. (1995). Evolution of the T cell reper- 
toire during the course of experimental autoimmune encephalomyeli- 
tis. Immunol. Rev. 144, 225-244. 
Mueller, D.L., Jenkins, M.K., and Schwartz, R.H. (1989). Clonal expan- 
sion versus functional clonal inactivation: a costimulatory signalling 
pathway determines the outcome of T cell antigen receptor occupancy. 
Annu. Rev. Immunol. 7, 445-480. 
Nabavi. N., Freeman, G.J., Gault, A., Godfrey, D., Nadler, L.M., and 
Glimcher, L.H. (1992). Signalling through the MHCclass II cytoplasmic 
domain is required for antigen presentation and induces 87 expres- 
sion. Nature 360, 265-269. 
Perrin, P.J., Scott, D., Quigley, L., Albert, P.S., Feder, O., Gray, G.S.. 
Abe, R., June, C.H., and Racke. M.K. (1995). Roleof B7:CD29/CTLA-4 
in the induction of chronic relapsing experimental allergic encephalo- 
myelitis. J. Immunol. 754, 1481-1490. 
Perry, L.L., and Barzaga, M.E. (1937). Kinetics and specificity of T 
and B cell responses in relapsing experimental allergic encephalomy- 
elitis. J. Immunol. 138, 1434-1441. 
Tan, L.J., Kennedy, M.K., Dal Canto, MC., and Miller, S.D. (1991). 
Successful treatment of paralytic relapses in adoptive experimental 
autoimmune encephalomyelitis via neuroantigen-specific tolerance. 
J. Immunol. 747, 1797-1802. 
Tuohy, V.K., Lu, 2, Sobel, R.A., Laursen, R.A., and Lees, M.B. (1989). 
Identification of an encephalitogenic determinant of myelin proteolipid 
protein for SJL mice. J. Immunol. 742, 1523-1527. 
Walunas, T.L., Lenschow, D.J., Bakker, C.Y., Linsley, P.S., Freeman, 
G.J., Green, J.M., Thompson, C.B., and Bluestone, J.A. (1994). 
CTLA-4 can function as a negative regulator of T cell activation. Immu- 
nity 7, 405-413. 
Wekerle, H. (1991). lmmunopathogenesis of multiple sclerosis. Acta 
Neurologica 13, 197-204. 
